-
Mashup Score: 17Podcast: Personalizing Locoregional Treatment for Breast Cancer - 3 month(s) ago
Dr. Dionisia Quiroga discusses emerging approaches to personalizing locoregional treatment for breast cancer with Drs. Walter Paul Weber and Charlote Coles, who share insights on tailoring axillary surgery, escalating lymphatic surgery, and implementing hypofractionated radiotherapy.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 14IMpassion132: Learning From Immunotherapy’s Failures in Early Relapsing Triple-Negative Breast Cancer - 5 month(s) ago
IMpassion132, a phase 3 trial of chemotherapy plus immune checkpoint inhibition in triple-negative breast cancer, was negative; however, it provided informative results for an understudied population with a poor prognosis.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
IMpassion132, a phase 3 trial of chemo + ICI for early relapsing triple-negative #BreastCancer, was a negative study that provided informative results for an understudied population. @CCortiMD & @IlanaSchlam dig into the results for #ASCODailyNews: https://t.co/BcCXTt40Xw #bcsm https://t.co/iUzMWkc0zk
-
-
Mashup Score: 21
Dr. Allison Zibelli and Dr. Erika Hamilton discuss the results of the DESTINY-Breast06 trial in HR+, HER2-low and HER2-ultralow metastatic breast cancer and the A-BRAVE trial in early triple-negative breast cancer, the results of which were both presented at the 2024 ASCO Annual Meeting.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
🎙️ Dr. Allison Zibelli of @KimmelCancerCtr & @ErikaHamilton9 of @SarahCannonDocs discuss DESTINY-Breast06 + A-BRAVE & their implications for the future treatment of patients with #BreastCancer on the #ASCODailyNews Podcast: https://t.co/0CcrxgOF1G #bcsm https://t.co/FrUrs9ITBz
-
-
Mashup Score: 7Podcast: How to Enhance Early-Stage Breast Cancer Survivorship - 6 month(s) ago
Drs. Hope Rugo, Diana Lam, Sheri Shen, and Mitchell Elliott discuss key strategies and emerging technology in early-stage breast cancer survivorship, including mitigating risk through lifestyle modification, surveillance for distant recurrence, and optimization of breast imaging.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
🎙️@hoperugo of @UCSFCancer, Dr. Diana Lam of @FredHutch, @SherryShenMD of @MSKCancerCenter & @MitchElliott18 of @pmcancercentre highlight key strategies for early-stage #BreastCancer survivorship on the #ASCODailyNews Podcast: https://t.co/pbuWKek6qK #bcsm https://t.co/xpMmC1HtQq
-
-
Mashup Score: 10ASCO Updates Early Breast Cancer Guideline to Include Adjuvant Use of CDK4/6 Inhibitors - 8 month(s) ago
As a result of follow-up data from the monarchE and NATALEE trials, ASCO has made a rapid recommendation update addressing when abemaciclib and ribociclib may be offered to patients with stage II/III breast cancer in the adjuvant setting.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Based on follow-up data from monarchE & NATALEE, our new rapid recommendation update addresses when abemaciclib & ribociclib should be administered for stage II/III #breastcancer in the adjuvant setting. #ASCODailyNews has more: https://t.co/yzyllk5lV4 #BCSM @MDAndersonNews https://t.co/uwRqdJWtxM
-
-
Mashup Score: 23
Drs. Hope Rugo and Sara Tolaney discuss the promise of antibody-drug conjugates (ADCs) in the treatment of breast cancer, highlighting key trials that shed light on matching the right ADC to the right patient in the right setting. They also explore how combinations and sequencing of ADCs can augment their efficacy, the mechanisms of resistance, and the future potential of biomarkers to predict patient response.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
🎙️ @hoperugo of @UCSFCancer and @stolaney1 of @DanaFarber discuss the promise of ADCs in #BreastCancer + key trials that inform sequencing, mechanisms of resistance & managing toxicities on the #ASCODailyNews Podcast: https://t.co/UEWZp3EIvn #bcsm https://t.co/8nWYfA4oVu
-
-
Mashup Score: 23The Evolving Role of CDK4/6 Inhibitors in the Treatment of Advanced and Early-Stage Breast Cancer: Lessons Learned From SONIA and NATALEE - 11 month(s) ago
Recent data from the SONIA and NATALEE trials further solidify CDK4/6 inhibitors within the breast cancer treatment landscape, but challenges, including cost and toxicity should be further addressed before wide application across practice.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
SONIA & NATALEE have further solidified CDK4/6 inhibitors in the #BreastCancer landscape, but challenges like cost & toxicity should be addressed before they are applied widely. @AlbertGrinshpun & @PTarantinoMD review the data for #ASCODailyNews: https://t.co/N5Rs8tw5kz #bcsm https://t.co/uvBIOK6J3y
-
🎙@quirogad of @OSUCCC_James, Dr. Walter Paul Weber of @UniSpitalBasel & Dr. Charlotte Coles of @Cambridge_Uni discuss personalizing locoregional treatment for #BreastCancer on the #ASCODailyNews Podcast: https://t.co/UMIXhZphid #bcsm https://t.co/c8tsV6J2lS